For medical oncologist and researcher Shipra Gandhi, MD, Assistant Professor of Oncology specializing in breast cancer in the Department of Medicine at Roswell Park Comprehensive Cancer Center, the path to physician-scientist was clear from
For Anna Woloszynska, PhD, the path to running one of the nation’s top cancer research programs began nearly 4,000 miles away in forests and rivers near the Baltic Sea.
Throughout the year, we’ve been honored to bring you news of the latest research, health tips for patients and caregivers alike, along with inspiring stories from patients and survivors.
"Being a researcher to me means I am always asking questions and looking for answers, which means I am constantly learning."
“I had never set foot in Buffalo and had no connections here. People ask me, ‘Why did you choose Roswell then?’ It’s simple: the people."
When you think of clinical research, you may picture doctors and scientists collecting data or patients trying new treatment regimens. However, some very important people are missing from this picture: clinical research nurses.
Candace Johnson, PhD, President and CEO of Roswell Park Comprehensive Cancer Center, didn’t imagine becoming a scientist when she was young. She wanted to be a ballerina.
When asked what interests her more about her work – being a clinician or a researcher – Dr. Griffiths answers that both do.
“I experienced the wonderful feeling of being able to provide real hope to people suffering from cancer.”
Among other projects, she and her colleagues are looking for ways to harness the power of stress to make allogeneic bone marrow transplants safer, improve outcomes for radiation and immunotherapies, and provide a new treatment strategy for patients with advanced melanoma.
Dr. Wooten's grandfather was diagnosed with metastatic lung cancer the summer before she began her medical education at the University of Florida College of Medicine. Her family's experience during that time has shaped the way she cares for her own patients at Roswell Park.
In 2019, Pamela Hershberger, PhD, came upon a stunningly significant finding in her research lab. Dr. Hershberger, Associate Professor of Oncology in Roswell Park’s Department of Pharmacology and Therapeutics, says she and her team had been “studying patients with a particular type of lung cancer — EGFR mutant lung cancer — and their response to a specific class of drugs called EGFR tyrosine kinase inhibitors.